These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20136626)

  • 1. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.
    Reikvam H; Olsnes AM; Gjertsen BT; Ersvar E; Bruserud Ø
    Crit Rev Oncog; 2009; 15(1-2):1-41. PubMed ID: 20136626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
    Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
    Zhou J; Ching YQ; Chng WJ
    Oncotarget; 2015 Mar; 6(8):5490-500. PubMed ID: 25823927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-κB inhibition in acute myeloid leukemia cells.
    Zhang H; Xu H; Zhang R; Zhao X; Liang M; Wei F
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):257-266. PubMed ID: 32696214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NF-κB activity in myeloid leukemia stem cells].
    Kagoya Y
    Rinsho Ketsueki; 2015 Apr; 56(4):384-91. PubMed ID: 25971268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.
    Bruserud Ø; Reikvam H
    Expert Opin Ther Targets; 2010 Nov; 14(11):1139-42. PubMed ID: 20942744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of microRNA-125b inhibits human acute myeloid leukemia cells invasion, proliferation and promotes cells apoptosis by targeting NF-κB signaling pathway.
    Wang Y; Tang P; Chen Y; Chen J; Ma R; Sun L
    Biochem Biophys Res Commun; 2017 Jun; 488(1):60-66. PubMed ID: 28478034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive NF-κB activation in AML: Causes and treatment strategies.
    Bosman MC; Schuringa JJ; Vellenga E
    Crit Rev Oncol Hematol; 2016 Feb; 98():35-44. PubMed ID: 26490297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
    Jenkins C; Hewamana S; Gilkes A; Neelakantan S; Crooks P; Mills K; Pepper C; Burnett A
    Br J Haematol; 2008 Dec; 143(5):661-71. PubMed ID: 19036014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.
    Fuchs O
    Curr Mol Pharmacol; 2010 Nov; 3(3):98-122. PubMed ID: 20594187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics.
    Reikvam H
    Cells; 2020 Jul; 9(7):. PubMed ID: 32664684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
    Breccia M; Alimena G
    Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR4/NF-κB axis induces fludarabine resistance by suppressing TXNIP expression in acute myeloid leukemia cells.
    Huy H; Kim TD; Kim WS; Kim DO; Byun JE; Kim MJ; Park YJ; Yoon SR; Noh JY; Lee J; Lee KH; Choi I; Jung H
    Biochem Biophys Res Commun; 2018 Nov; 506(1):33-40. PubMed ID: 30336978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TAK1-NF-κB axis as therapeutic target for AML.
    Bosman MC; Schepers H; Jaques J; Brouwers-Vos AZ; Quax WJ; Schuringa JJ; Vellenga E
    Blood; 2014 Nov; 124(20):3130-40. PubMed ID: 25287709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
    Kagoya Y; Yoshimi A; Kataoka K; Nakagawa M; Kumano K; Arai S; Kobayashi H; Saito T; Iwakura Y; Kurokawa M
    J Clin Invest; 2014 Feb; 124(2):528-42. PubMed ID: 24382349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
    Omsland M; Bruserud Ø; Gjertsen BT; Andresen V
    Oncotarget; 2017 Jan; 8(5):7946-7963. PubMed ID: 27974700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oroxylin A, a natural compound, mitigates the negative effects of TNFα-treated acute myelogenous leukemia cells.
    Li H; Lu N; Yu X; Liu X; Hu P; Zhu Y; Shen L; Xu J; Li Z; Guo Q; Hui H
    Carcinogenesis; 2018 Oct; 39(10):1292-1303. PubMed ID: 29346508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZNF460-regulated COMMD7 Promotes Acute Myeloid Leukemia Proliferation Via the NF-κB Signaling Pathway.
    Shao X; Zhong L; Chu X; Wan P; Chen S; Zhou Z; Zhang H; Wang M; Liu B
    Int J Med Sci; 2023; 20(4):520-529. PubMed ID: 37057209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.
    Li J; Volk A; Zhang J; Cannova J; Dai S; Hao C; Hu C; Sun J; Xu Y; Wei W; Breslin P; Nand S; Chen J; Kini A; Zhu J; Zhang J
    Oncotarget; 2017 Jan; 8(5):8420-8435. PubMed ID: 28039479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of NF-κB inhibitor in Acute Myeloid Leukemia].
    Wang WL; Xu QZ; Mu XH; Wang L; Zhang LY; Xu J; Gao YD; Cheng T; Yuan WP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1622-1626. PubMed ID: 28024466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.